Filtered By:
Management: Insurance
Countries: Canada Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 17 results found since Jan 2013.

'We feel we can breathe again': Blue Cross reverses course, will cover Sask. man's $500K medical bills
The family of Louis Lamothe, a Halbrite, Sask. man who suffered a stroke while vacationing in Arizona and incurred thousands of dollars in travel and medical bills, is resting easier now that Saskatchewan Blue Cross, which had denied their travel insurance claim, has had a change of heart.
Source: CBC | Health - March 3, 2023 Category: Consumer Health News Tags: News/Canada/Saskatoon Source Type: news

This Sask. man had a stroke in Arizona. His family awaits massive bill after insurance claim denied
After a man from Halbrite, Sask,, had a stroke while vacationing in Arizona, his family learned they were on the hook for a $56,000 flight home — and other medicals bills yet to come in — as their health insurance was cancelled.
Source: CBC | Health - February 28, 2023 Category: Consumer Health News Tags: News/Canada/Saskatoon Source Type: news

Cardiovascular disease and the risk of dementia: a survival analysis using administrative data from Manitoba
CONCLUSION: A diagnosis of CVD is associated with an increased risk of a future diagnosis of dementia. Promoting good cardiovascular health may serve as an effective measure for preventing dementia.PMID:35025100 | DOI:10.17269/s41997-021-00589-2
Source: Canadian Journal of Public Health - January 13, 2022 Category: International Medicine & Public Health Authors: Luc Clair Hope Anderson Christopher Anderson Okechukwu Ekuma Heather J Prior Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Costs of surgical ablation of atrial fibrillation in Ontario, Canada from 2006 to 2017
ConclusionOntario taxpayers spend significant financial resources on surgical ablation of AF, a procedure lacking high ‐quality evidence demonstrating benefit in reducing mortality or stroke. Further large prospective studies examining clinically important outcomes are needed to justify its routine use in patient care and to guide allocation of healthcare funds.
Source: Journal of Cardiac Surgery - September 27, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Justin Y. Chow, Graham McClure, Emilie P. Belley ‐Côté, William F. McIntyre, Rohit K. Singal, Richard P. Whitlock Tags: ORIGINAL ARTICLE Source Type: research

Oral Anticoagulants and Antiplatelet Agents in Atrial Fibrillation Patients with Concomitant Critical Limb Ischemia: A nationwide cohort study
ConclusionsDOAC was associated with a significantly lower risk of composite net-clinical-benefit outcome than either warfarin or APT in AF patients with concomitant CLI. Further prospective study is necessary to validate the findings in the future.
Source: Canadian Journal of Cardiology - February 19, 2020 Category: Cardiology Source Type: research

Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - January 16, 2020 Category: Cardiology Source Type: research

How to Keep Alzheimer ’s From Bringing About the Zombie Apocalypse
I tried to kill my father for years. To be fair, I was following his wishes. He’d made it clear that when he no longer recognized me, when he could no longer talk, when the nurses started treating him like a toddler, he didn’t want to live any longer. My father was 58 years old when he was diagnosed with Alzheimer’s disease. He took the diagnosis with the self-deprecating humor he’d spent a lifetime cultivating, constantly cracking jokes about how he would one day turn into a zombie, a walking corpse. We had a good 10 years with him after the diagnosis. Eventually, his jokes came true. Seven years ...
Source: TIME: Health - November 20, 2019 Category: Consumer Health News Authors: Jay Newton-Small Tags: Uncategorized Alzheimer's Disease Source Type: news

Efficacy and Safety of High-intensity Statins in Patients with Acute Myocardial Infarction: An Asian Perspective
ConclusionsAMI patients in Taiwan with HIS had similar clinical outcomes to those with non-HIS. Using HIS for effective reduction of low-density lipoprotein cholesterol is safe in Taiwan.
Source: Canadian Journal of Cardiology - November 2, 2019 Category: Cardiology Source Type: research

Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada
AbstractCanadian guidelines recommend non vitamin K antagonists (NOACs) in preference to vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation (AF), but NOACs are more expensive than VKAs. Canada has a universal healthcare system that covers the cost of NOACs for select patient groups. Ability to pay for NOACs may influence their use. We reviewed medical charts of Hamilton General Hospital outpatients under the age of 65 with a new diagnosis of AF who were referred for initiation of OAC therapy. We contacted these patients by phone and asked them to complete a questionnaire regarding their...
Source: Journal of Thrombosis and Thrombolysis - June 5, 2018 Category: Hematology Source Type: research

Risk of stroke in patients with dengue fever: a population-based cohort study.
Authors: Li HM, Huang YK, Su YC, Kao CH Abstract BACKGROUND: Stroke is a severe neurologic complication of dengue fever, described in only a few case reports. The incidence and risk factors for stroke in patients with dengue remain unclear. We conducted a population-based retrospective cohort study to investigate the risk of stroke in patients with dengue. METHODS: Using data from the Taiwan National Health Insurance Research Database, we included a total of 13 787 patients with dengue newly diagnosed between 2000 and 2012. The control cohort consisted of patients who did not have dengue, matched 1:1 by demogra...
Source: Canadian Medical Association Journal - March 14, 2018 Category: General Medicine Tags: CMAJ Source Type: research